Comparison · NCT02605642-0523b9ce
Biologic Disease Modifying Anti-Rheumatic Drugs (BDMARD) Naive vs Participants Who Switched From Remicade to CT-P13: Number of Participants With Change in CT-P13 Infusion Dose
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Biologic Disease Modifying Anti-Rheumatic Drugs (BDMARD) Naive vs Participants Who Switched From Remicade to CT-P13: Number of Participants With Change in CT-P13 Infusion Dose. Trial comparisons, record NCT02605642-0523b9ce. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02605642-0523b9ce
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.181 | 0.136 | 0.237 | wilson | |
| Risk in group 2 | 0.0748 | 0.0384 | 0.141 | wilson | |
| Risk difference, group 1 minus group 2 | 0.106 | 0.0264 | 0.173 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.42 | 1.17 | 4.99 | log | |
| Odds ratio, group 1 over group 2 | 2.73 | 1.23 | 6.07 | log | |
| Number needed to treat, for one more participant with the outcome on Biologic Disease Modifying Anti-Rheumatic Drugs (BDMARD) Naive than on Participants Who Switched From Remicade to CT-P13 | 9.41 | 5.78 | 37.9 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Biologic Disease Modifying Anti-Rheumatic Drugs (BDMARD) Naive | BDMARD naive participants who were receiving CT-P13 according to the summary of product characteristics (SmPC and Product Monograph) as determined by the investigator, were included in this group and observed in this study for a duration of up to 2 years. | 40 | 221 | OG000 |
| Group 2 | Participants Who Switched From Remicade to CT-P13 | Participants who were previously treated with Remicade, switched to CT-P13 and started receiving CT-P13 (according to the SmPC and Product Monograph; as determined by the investigator) from stable treatment with Remicade, were included in this group and observed for a duration of up to 2 years. | 8 | 107 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Change in CT-P13 Infusion Dose
- Description
- Participants who had change in the dose of infusion (either dose reduction or increase in dose) during the observation period were reported.
- Time frame
- During the observation period of 2 years
- Population
- The safety population was defined as all participants who received at least one dose of CT-P13 during the study observation period.
Source ClinicalTrials.gov
Trial
- Title
- Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade
- NCT number
- NCT02605642
- Phases
- Conditions
- Rheumatoid Diseases, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Interventions
- CT-P13
- Lead sponsor
- Pfizer
- Results first posted
- 2020-01-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02605642?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02605642-0523b9ce